TGFB1 and Hepatic fibrosis: Shaker et al. (2011a,b,c, 2013) found that nilotinib had a promising anti-fibrotic activity in experimental models of liver fibrosis by inhibiting activation of HSCs (Shiha et al., 2014). Liu et al. (2011) also reported that nilotinib significantly inhibited PDGF and TGF-β-simulated activation of ERK and Akt and consequently reduced collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrotic models.